world is news

WHO and Sanofi renew decades-long collaboration to maintain elimination efforts

Spread the news

The World Health Organization (WHO) and Sanofi – one of many world’s main pharmaceutical corporations – have signed a brand new settlement for donations of medicines to maintain particular efforts to eradicate uncared for tropical ailments (NTDs).

“This decades-long collaboration exemplifies a successful public–private partnership that has created meaningful impact in several countries and has brought sleeping sickness closer to elimination,” stated Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “In a world severely disrupted by the current pandemic, Sanofi’s renewed commitment and support to end this disease will immensely benefit and improve the lives of marginalized populations.”

Under the brand new five-year US$ 25 million settlement (2021–2025), Sanofi will assist WHO’s international programme for elimination of human African trypanosomiasis (sleeping illness), leishmaniasis, management and prevention of Chagas illness and built-in management of the pores and skin NTDs.1

“Sanofi has been collaborating for 20 years with the World Health Organization in the fight against neglected tropical diseases (NTDs). The renewal of this collaboration today speaks volumes about our longstanding engagement in global health” indicated Paul Hudson, CEO Sanofi. “We also welcome the recent endorsement of the new NTDs roadmap by the World Health Assembly. Sanofi is committed to further contribute to the elimination of sleeping sickness, including advancing research and development for vulnerable communities exposed to the disease.”

Beyond elimination of human African trypanosomiasis as a public well being drawback

Sanofi’s dedication to eradicate sleeping illness has been unfaltering. At the flip of the century, when hundreds of circumstances have been detected yearly, the corporate supported investments in analysis and improvement of latest medicines.

With the donation of medicines, mixed with work of motivated well being care staff, the variety of sleeping illness circumstances has decreased from 33 000 in 2000 to fewer than 1000 in 2019, eclipsing the unique goal of elimination as a public well being drawback by 2020.2

The latest addition of fexinidazole – an oral remedy for sleeping illness, has been largely supported by Sanofi and the Drugs for Neglected Diseases initiative. This has boosted the extra bold prospects of interruption of transmission by 2030, much more in order Sanofi continues its funding in enhancing therapeutic instruments with the event of latest medicines similar to acoziborole, presently below superior scientific trials

The settlement signed throughout a digital assembly between Dr Tedros and Mr Paul Hudson, Chief Executive Officer of Sanofi on 10 December 2020, will allow WHO to coordinate the supply of donated medicines. Under this new settlement, funding may also be earmarked for in-country capacity-strengthening and coaching of well being staff, improved epidemiological surveillance, and renewed efforts for case-finding and remedy for a number of ailments, together with leishmaniasis, Chagas illness and the pores and skin NTDs.

Two many years of collaboration

Collaboration between WHO and Sanofi began in 2001 when the corporate, then referred to as Aventis Pharma, dedicated US$ 25 million to assist the management and prevention of sleeping illness, initially for a interval of 5 years.

The settlement was renewed in 2006 and included assist for different NTDs similar to Buruli ulcer, Chagas illness, leishmaniasis and yaws. Subsequently, it was renewed each 5 years. Since 2001 and with this new dedication, Sanofi’s in-kind and in-cash assist is reaching US$ 125 million.


Of the 20 NTDs, greater than half current with pores and skin manifestations and are related to long-term incapacity, stigmatization and psychological well being issues. These embrace Buruli ulcer, cutaneous leishmaniasis, leprosy, mycetoma, yaws, onchocerciasis, lymphatic filariasis and scabies. All these ailments require related detection and case-management approaches.

2 Elimination as a public well being drawback is outlined by reaching measurable international targets set by WHO in relation to a particular illness. When reached, continued actions ought to proceed to take care of the targets and/or to advance the interruption of transmission.


Spread the news